PHARMAKURE - Key Persons

Job Titles:

• Scientist ( Assay Development )

Job Titles:

• Clinical Director

Job Titles:

• Formulation and Patent Expert

Job Titles:

• Scientific & Biomarker Advisor
• Scientific & Biomarker Advisor / Professor Sir Alan Fersht

Dr. Stanley was a co-founder of CynapseDx and Circular1 Health.

Job Titles:

• CEO
• Chairman
• CEO and Chair of Pharma
• Co - Founder of PharmaKure Ltd.

Dr. Farid Khan is a co-founder of PharmaKure Ltd. He has worked previously for GlaxoSmithKline as a drug discovery scientist and had academic positions in biotechnology at The Babraham Institute in Cambridge and at The University of Manchester. He also founded a CRO in biotech services which specialises in recombinant DNA technology; a drug repurposing company focused on Alzheimer's disease; an artificial intelligence company focused on image based diagnosis of cancers; and a med-tech platform delivering medication adherence during clinical trials. He works with third party biotech and pharmaceutical companies undertaking biotech deal flows, including the licensing of drug assets. He has published papers in peer reviewed journals - including fast-tracking new indications for drugs for malaria. He has formed key interdisciplinary collaborations with industry, academic institutions and charities (such as the Welcome Trust) including stakeholders in the UK's healthcare agenda. Dr Khan has previously received awards including ‘excellence in engineering/ science/ technology' by the former Prime Minister David Cameron and an Alumni Achievement Award in science and engineering from the University of Salford. He has a PhD in protein engineering, a MSC in parasitology and a BSc in Chemistry. He is a senior Research Associate in Biotech and Enterprise at Peterhouse, The University of Cambridge. Dr Farid Khan, CEO and Chair of PharmaKure has a background in assay development and HTS for drug discovery from GlaxoSmithKline. In this interview in ASSAY and Drug Development Technologies he discusses future prospects of drug repurposing.

Job Titles:

• Lead Scientist ( Clinical Trials )

Job Titles:

• Repurposing Strategy Advisor

Job Titles:

• CCO
• Assisting Neuron Wellness
• Co - Founder and Former CEO of Algae
• Member of the International Board of Advisors for the Vector Innovation Fund

Dr Naz Bashir has over twenty years of experience as an entrepreneur in early stage companies, in/out licensing, investment strategies and in commercial and business development. He has achieved success in driving sales from licensing, strategic partnerships in the biotech, chemicals, biofuels and food sectors; deal packages ranging up to $100M. Dr Bashir has held executive roles and raised finance as part of the management team with a nutraceutical company, an oil and gas company, a biopharmaceutical company, and a biosensor company. Naz managed a university seed fund achieving out licensing of biological technologies, chemical assets and value through exits and an IPO. More recently, he co-founded an Omega 3 company in which he invested in and successfully raised an EIS round which is leading to strategic investments/partnerships. He also acts as advisor, consultant and is a non-executive director on a couple of early stage biotech in digital wound care (antimicrobial), gut health (microbiome) and a digital therapeutics incubator. He has a PhD in Chemistry and an MBA from the University of Exeter. Dr. Naz Bashir is a co-founder and former CEO of AlgaeCytes, a nutraceutical company that produces Omega 3 from algae. In the following article Dr. Bashir explains "Because the world's population is on a very dramatic increase, we do need to have a sustainable means of producing these omega 3 oils". Dr. Naz Bashir is a member of the International Board of Advisors for The Vector Innovation Fund. The Vector Innovation Fund is a Reserved Alternative Investment Fund (RAIF) specialising in support for technology companies able to transform global markets, notably in global healthcare, sustainability and longevity. These transformational technologies come from the nanotechnology, biotech, AI and machine learning, foodtech, cleantech and spacetech sectors. Dr. Naz Bashir is a NED of Neuron Wellness Limited. An exciting health technology company dedicated to reshaping the behavioral and educational landscape of health, fitness, nutrition and wellness. The Company uses science and data to help customers (consumers and corporates) with personalized wellness products and services to change behavior and make choices through enhanced knowledge of health/wellness/nutrition via connected technologies and tools. It can deliver a proven and highly efficient route to targeting. Maintaining gut bacterial balance is now recognized as one of the most influential components when it comes to maintaining wellness.

Job Titles:

• Honorary Professor in the Biomolecular Sciences Research Centre at Sheffield Hallam University

Gavin Reynolds is Honorary Professor in the Biomolecular Sciences Research Centre at Sheffield Hallam University and Professor Emeritus, formerly Chair of Neuroscience, at Queen's University Belfast. He also has an honorary research position at Rotherham, Doncaster and South Humber NHS Trust. After a biochemistry PhD, he undertook postdoctoral work in London, also spending approximately 18 months working in Vienna, moving in 1982 to Cambridge where he supervised the MRC Brain Bank. In 1985 he took up a Wellcome Lectureship at the University of Nottingham, moving in 1990 to the University of Sheffield and in 2004 to take up the Chair of Neuroscience in the Dept of Psychiatry at Queen's University Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and epigenetic influences. Additional interests include neurodegenerative disease mechanisms and biological effects of substance abuse. He has well over 300 research publications, with an h-index of 84. He has international collaborations with Visiting Professor appointments at universities in Thailand and China. He is a past president of the British Association for Psychopharmacology. by restoring the activity of mutated proteins. Since October 2012-2018, he has been Master of Gonville and Caius College, Cambridge. Knighted in 2003 for his work on protein science, and has honorary degrees from Uppsala, Brussels, Weizmann Institute, Imperial College and The Hebrew University. He has honorary professorships in China in Shanghai, Chengdu and Qingdao. He has world-wide experience in the needs of science and biotechnology.

Job Titles:

• Technical Manager

Mr. Bond was the Founder & Chief Executive of Platform Diagnostics and ProKyma Technologies. He has founded four life sciences / diagnostics companies and one clean tech company. Whilst commercially focused, he is also an inventor on over 11 patent applications. Most recently Mr. Bond was the CEO and co-founder of CynapseDx.

Job Titles:

• CFO
• Chairman of the Audit Committee for Alzamend Neuro™, Inc
• Chairman of the of Audit Committee for a NASDAQ Listed Company
• Chartered Professional Accountant
• Member of CPABC
• Member of the Chartered Professional Accountants of British Columbia

Mark Gustafson is chairman of the Audit Committee for Alzamend Neuro™, Inc., ("Alzamend™"). Alzamend is a Delaware corporation with its headquarters in Atlanta, Georgia with nexus in California, is a clinical-stage, biopharmaceutical company. Alzamend strives to provide hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development. Mark Gustafson is a member of The Chartered Professional Accountants of British Columbia (CPABC), which is the training, governing, and regulatory body for over 38,000 CPA members and 6,000 CPA candidates.

Job Titles:

• Scientific & Biomarker Advisor / Professor Sir Alan Fersht

Job Titles:

• Professor of Chemical and Molecular

Sophie Jackson is professor of Chemical and Molecular Biology in the Yusuf Hamied Department of Chemistry, University of Cambridge Prof. Jackson's is a world-leading scientist in the areas of protein folding and peptide aggregation and research at the interface of chemistry and biological sciences. Prof. Jackson's experimental work covers diverse areas including biophysics, molecular biology (including protein engineering) and chemical biology. Recently she has studied protein misfolding and aggregation of amyloid β (Aβ) and α-synuclein (α-syn) that form amyloid fibrils in Alzheimer's and Parkinson's diseases, respectively, a process that is intimately linked to the diseases' progression. In addition, her work has led to elucidating factors that affects physical stability of peptides that are important in developing therapeutics for disease.